-

04:57:40 AM

SVA Stock News

SVA - Sinovac Biotech, Ltd.

05/10/23 5:51 AM

Nasdaq : SVA

covid-19

SINOVAC’s CoronaVac® Answers Hong Kong’s Need for Self-Pay COVID-19 Vaccines

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced it will provide its inactivated COVID-19 vaccine, CoronaVac ®, to self-paying groups in Hong Kong. Additionally, the company will collaborate with local charity groups to provide donations, giving more children in Hong Kong access to free vaccines to protect...

RHEA-AI

neutral

05/01/23 6:00 AM

Nasdaq : SVA

earnings

SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, has filed its 2022 annual report on Form 20- F with the U.S. Securities and Exchange Commission for the year ended December 31, 2022. The Company also reported its unaudited financial for the second half and audited financial for full year ended December 31, 2022..

RHEA-AI

neutral

02/22/23 6:00 AM

Nasdaq : SVA

Sinovac Amends Shareholder Rights Plan

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan. Sinovac Biotech Ltd. is a China- based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

RHEA-AI

neutral

12/29/22 8:30 AM

Nasdaq : SVA

earnings

SINOVAC Reports Unaudited First Half of 2022 Financial Results

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2022. Sales for the six-month period ended June 30, 2022 were $1.2 billion, compared to $11.0 billion in the prior year period. Net income attributable to common shareholders totaled...

RHEA-AI

neutral

11/03/22 10:03 PM

Nasdaq : SVA

SINOVAC Varicella Vaccine Prequalified by WHO

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, today announced that it received prequalification from the World Health Organization for its live attenuated varicella vaccine on November 3, 2022. This marks the first WHO prequalified Chinese varicella vaccine and the fourth SINOVAC vaccine to receive WHO approval.

RHEA-AI

neutral

10/28/22 5:00 AM

Nasdaq : SVA

SINOVAC to Showcase Products at CPHI Frankfurt

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that the Company will participate in CPHI Frankfurt, one of the world’ s largest pharmaceutical exhibitions, from 1 st to 3 rd of November, in Frankfurt, Germany. At Booth #41 G20, the first floor of Hall 4, Messe Frankfurt, SINOVAC will greet all visitors of CPHI and present...

RHEA-AI

neutral

09/06/22 6:00 AM

Nasdaq : SVA

clinical trialcovid-19

SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that the Chilean Public Health Institute approved a phase II clinical trial for its inactivated Omicron strain COVID-19 vaccine and trivalent COVID-19 vaccine on August 31st. Weidong Yin, the Chairman, President, and CEO of SINOVAC said,“ SINOVAC has made great...

RHEA-AI

neutral

08/18/22 5:56 PM

Nasdaq : SVA

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sinovac To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against 1Globe Capital LLC ("1Globe") on behalf of a class consisting of all holders of Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ:SVA) stock

RHEA-AI

negative

08/03/22 6:00 AM

Nasdaq : SVA

covid-19

SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that based on related clinical trials and studies of vaccination for local children and adolescents, the Health Bureau of the Government of the Hong Kong Special Administrative Region of the People’ s Republic of China has approved the Company’ s COVID-19 vaccine,...

RHEA-AI

neutral

07/19/22 1:30 AM

Nasdaq : SVA

clinical trial

SINOVAC Initiates Clinical Trial for Its Quadrivalent Influenza Vaccine in Chile

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that a phase III clinical trial for SINOVAC’ s inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile through a collaboration with the Pontificia Universidad Católica de Chile. In total, there will be 1,600 volunteers recruited, half of...

RHEA-AI

neutral

SVA Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.sinovacbio.com
CeoWeidong Yin
Security nameSinovac Biotech, Ltd.
Issue typecs
SectorManufacturing
Sic code2834
Employees4281
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
AddressNo. 15 Zhi Tong Road,
Address2Zhongguancun Tech Park, Changping Distr.
StateBeijing
CityBeijing
Zip102200
CountryChina (Mainland)
Phone861082890088

About Sinovac Biotech, Ltd.

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Sinovac's product portfolio includes vaccines against enterovirus71 (EV71), hepatitis A and B, seasonal influenza, 23-Valent Pneumococcal Polysaccharide ('PPV'), H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu), varicella vaccine and mumps. Healive, the hepatitis A vaccine manufactured by the Company, has passed the assessment under WHO prequalification procedures in 2017. The EV71 vaccine, an innovative vaccine developed by Sinovac against hand foot and mouth disease caused by EV71, was commercialized in China in 2016. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, which it has supplied to the Chinese Government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government stockpiling program. The Company is developing a number of new products including COVID-19 vaccine, CoronaVac, a Sabin-strain inactivated polio vaccine and combined vaccines. Sinovac primarily sells its vaccines in China, while also exploring growth opportunities in international markets. The Company is seeking market authorization of its products in over 30 countries outside of China.